The article discusses the current state of tau pathology research and therapeutic development for neurodegenerative diseases. Tauopathies, a group of over 20 neurodegenerative diseases, are characterized by the accumulation of abnormal tau protein. Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy are among the most common. Despite extensive research, no tau-targeted therapy has been approved for clinical use. The article reviews the biology and genetics of tau, the mechanisms of disease, and the challenges in developing effective therapies. It highlights the need for better biomarkers, more precise clinical trial designs, and a deeper understanding of tau's role in disease. The article also discusses the failure of many tau-targeted therapies and the reasons behind them, such as incorrect target identification and limitations in nonclinical models. It emphasizes the importance of understanding whether tau is a causal or bystander factor in disease. The article concludes with an optimistic outlook for future tau therapies, noting the progress in understanding tau's biology and the potential for new therapeutic approaches. It also highlights the need for diverse patient populations in clinical trials and innovative trial designs to improve the efficiency and effectiveness of tau therapy development.The article discusses the current state of tau pathology research and therapeutic development for neurodegenerative diseases. Tauopathies, a group of over 20 neurodegenerative diseases, are characterized by the accumulation of abnormal tau protein. Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy are among the most common. Despite extensive research, no tau-targeted therapy has been approved for clinical use. The article reviews the biology and genetics of tau, the mechanisms of disease, and the challenges in developing effective therapies. It highlights the need for better biomarkers, more precise clinical trial designs, and a deeper understanding of tau's role in disease. The article also discusses the failure of many tau-targeted therapies and the reasons behind them, such as incorrect target identification and limitations in nonclinical models. It emphasizes the importance of understanding whether tau is a causal or bystander factor in disease. The article concludes with an optimistic outlook for future tau therapies, noting the progress in understanding tau's biology and the potential for new therapeutic approaches. It also highlights the need for diverse patient populations in clinical trials and innovative trial designs to improve the efficiency and effectiveness of tau therapy development.